“Bridging the pharma-doctor gap with an inclusive, mobile-first solution”

Dr. Gunjan Kishor Sharma, a physician and passionate health tech innovator, is the driving force behind MeshApp.ai—a platform redefining communication and collaboration in the pharmaceutical and healthcare ecosystem. With firsthand experience of the fragmented interactions between pharma companies, medical reps, and doctors, Dr. Sharma founded MeshApp to bridge this gap through a tech-enabled, transparent, and inclusive solution.

In this interview, he shares insights into the platform’s impact, from enhancing field-force efficiency and compliance to empowering last-mile connectivity. He also outlines his vision of transforming MeshApp into a comprehensive digital backbone for the entire healthcare supply chain.

IBT: What inspired you to create MeshApp, and what specific problem in the pharmaceutical ecosystem were you aiming to solve?

Dr. Gunjan Kishor Sharma: As a medical professional, I frequently encountered a significant disconnect between pharmaceutical companies, their field force, and the doctors they strive to engage. Communication was often fragmented, critical updates were delayed or lost in transit, and the overall interaction felt more transactional than meaningful. Rather than fostering a sense of partnership, these engagements frequently lacked context, continuity, and transparency.

It became increasingly evident that the healthcare ecosystem was missing a cohesive, tech-driven platform that could unify these stakeholders—one that enabled seamless, timely, and value-driven communication. This realization was the catalyst for MeshApp.

MeshApp was created to address this very gap. It is a purpose-built solution designed to transform how pharmaceutical companies, medical representatives, and doctors connect and collaborate. By leveraging technology, MeshApp fosters a transparent and efficient environment that prioritizes trust, relevance, and mutual benefit. Our goal is to elevate the quality of engagement across the ecosystem, ultimately contributing to better healthcare outcomes for all.

IBT: In your experience, what are the most critical gaps or inefficiencies currently affecting pharmaceutical companies, especially in their sales and marketing operations?

Dr. Gunjan Kishor Sharma: One of the most critical challenges facing the pharmaceutical industry today is the absence of real-time communication and actionable insights from the field. Despite advances in digital tools, many sales teams still rely on outdated, manual reporting processes that slow down decision-making, reduce responsiveness, and hinder overall accountability. This lack of immediacy creates a disconnect between strategy and execution on the ground.

Furthermore, there’s limited visibility into the quality and effectiveness of medical representatives’ interactions with doctors. Without robust data, it’s difficult to assess engagement impact or tailor follow-ups. Product promotions often suffer from a lack of personalized targeting, resulting in generic messaging that fails to resonate with individual practitioners.

Compounding these issues is the growing emphasis on regulatory compliance. In an increasingly scrutinized environment, pharmaceutical companies must ensure every interaction is properly tracked and documented. However, traditional methods make this both cumbersome and inconsistent, leaving significant gaps in auditability and risk management.

These challenges underscore the urgent need for a technology-driven solution that not only streamlines operations but also brings greater clarity, efficiency, and compliance to every layer of field engagement.

IBT: How does MeshApp leverage technology to streamline communication and workflow between medical representatives, doctors, and pharma companies?

Dr. Gunjan Kishor Sharma: MeshApp serves as a secure, integrated platform designed to unify and streamline communication between verified medical professionals and pharmaceutical representatives. By bridging this longstanding gap, MeshApp enables seamless, real-time interaction that enhances both efficiency and engagement across the healthcare ecosystem.

For medical representatives, the platform offers powerful tools to schedule digital appointments, share up-to-date product information, and log visits with precision and immediacy. These features not only improve time management and accountability but also ensure that critical information reaches the right people at the right time.

For doctors, MeshApp is more than just a channel for pharmaceutical updates—it’s a dynamic professional space. Here, they can engage in peer discussions, explore emerging medical technologies, share clinical experiences, and stay informed on the latest developments. This collaborative environment fosters continuous learning and deeper connections within the medical community.

At its core, the platform transforms a traditionally fragmented process into a structured, data-driven interaction. Backed by robust analytics and real-time data capture, the platform delivers clarity, speed, and transparency—empowering stakeholders to make better-informed decisions and ultimately advancing the goal of improved healthcare outcomes.

IBT: Can you explain how MeshApp addresses issues like data transparency, field-force productivity, or real-time reporting — common challenges in pharma operations?

Dr. Gunjan Kishor Sharma: Absolutely. MeshApp brings powerful automation and transparency to field operations by streamlining visit logging, tracking representative movements, and delivering real-time dashboards for field managers. This integrated system offers unparalleled visibility into key performance metrics, engagement quality, and territory coverage—enabling leaders to monitor activity and outcomes with precision.

Every interaction on the platform is timestamped and securely documented, ensuring full traceability and audit readiness. This not only enhances compliance but also builds trust across stakeholders by promoting accountability at every level.

Armed with actionable, data-driven insights, companies can respond swiftly to emerging trends, identify performance gaps, and deploy targeted interventions such as training, mentorship, or support. By replacing guesswork with real-time intelligence, MeshApp empowers organizations to make faster, smarter decisions—ultimately driving higher productivity, better field-force alignment, and stronger healthcare partnerships.

IBT: What has been the response from pharma companies so far? Are there any measurable impacts or success stories you can share since MeshApp’s implementation?

Dr. Gunjan Kishor Sharma: The response to MeshApp has been overwhelmingly positive, reaffirming the critical need for a solution like this in the pharmaceutical ecosystem. Early adopters—both pharmaceutical companies and healthcare professionals—have reported significant improvements across multiple dimensions. Several pharma partners have noted a marked increase in doctor engagement, enhanced compliance tracking, and a substantial reduction in reporting delays. Notably, one of our early partners observed a 40% improvement in the accuracy of meeting documentation within just three months of implementation.

On the doctors’ side, the feedback has been equally encouraging. Many have expressed appreciation for the platform’s transparency, intuitive interface, and the ease with which they can access timely, relevant updates on new drugs—without the usual noise or disruption. The ability to engage on their own terms, with greater control and clarity, has added meaningful value to their daily practice.

While we’re still in the early stages of deployment, the strong initial traction and measurable outcomes are a clear validation that MeshApp is addressing a real, persistent gap in the system. It’s a promising start—and one that motivates us to keep evolving the platform in step with the needs of the industry.

IBT: The pharma sector is often criticised for a lack of digital transformation in field operations. How does MeshApp help bridge this digital gap, especially in semi-urban and rural regions?

Dr. Gunjan Kishor Sharma: We’ve designed MeshApp with inclusivity and accessibility at its core, ensuring that it works seamlessly across geographies and user profiles. The platform is lightweight, mobile-first, and optimized for performance even in low-bandwidth environments—making it ideal for representatives operating in Tier 2, Tier 3 cities, and rural regions. Field reps can continue using the app offline, with data automatically syncing once connectivity is restored. This ensures uninterrupted workflows, regardless of location or network availability.

In addition, MeshApp features a localized user interface with multilingual support, enabling both medical representatives and doctors in non-metro areas to navigate the platform with ease and confidence. By removing language and connectivity barriers, we’ve made digital adoption frictionless and intuitive for users who are often underserved by conventional tech solutions.

This kind of thoughtful, inclusive design is essential for driving true digital transformation in pharma—especially when it comes to empowering the last mile of field operations, where the need for efficiency and support is most acute.

IBT: Looking ahead, what is your vision for MeshApp in the next five years? Do you plan to expand its use beyond the pharmaceutical industry?

Dr. Gunjan Kishor Sharma: In the next five years, we envision MeshApp evolving into the go-to digital platform for all stakeholders across the healthcare ecosystem—not limited to just pharmaceutical companies. Our long-term vision is to create a unified, intelligent infrastructure that supports seamless collaboration, data-driven decision-making, and operational efficiency across the entire healthcare value chain.

Our product roadmap includes the integration of advanced technologies such as AI-driven insights for intelligent rep-doctor matchmaking, predictive analytics to forecast product demand, and automated workflows to simplify administrative tasks like accounting, compliance, and reporting. These innovations will not only boost productivity but also enhance personalization and precision in stakeholder engagement.

Beyond pharma, we are actively exploring expansion into adjacent verticals including diagnostics, insurance, and healthcare logistics. By connecting these critical components, we aim to build a truly interconnected, digital-first ecosystem that delivers end-to-end value—from product development and distribution to patient care and outcomes. This vision reflects our commitment to enabling smarter, more inclusive healthcare delivery for the future.